Skip to main content

Drug Interactions between crinecerfont and pexidartinib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

pexidartinib crinecerfont

Applies to: pexidartinib and crinecerfont

ADJUST DOSE: Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of crinecerfont, which is primarily metabolized by the isoenzyme. Concomitant use with rifampin, a potent CYP450 3A4 inducer, decreased crinecerfont peak plasma concentration (Cmax) and systemic exposure (AUC) by 23% and 62%, respectively. No data are available for other, less potent inducers. Reduced efficacy of crinecerfont may occur.

MANAGEMENT: When coadministered with moderate CYP450 3A4 inducers, the crinecerfont evening dose should be increased.
In adults, increase the crinecerfont dose to 200 mg with a meal in the evening (morning dose of 100 mg with a meal remains unchanged).

In pediatric patients 4 years of age and older, increase the crinecerfont dose based on weight:
-Patients weighing 10 kg to less than 20 kg: 50 mg with a meal in the evening (morning dose of 25 mg with a meal remains unchanged)
-Patients weighing 20 kg to less than 55 kg: 100 mg with a meal in the evening (morning dose of 50 mg with a meal remains unchanged)
-Patients weighing 55 kg or more: 200 mg with a meal in the evening (morning dose of 100 mg with a meal remains unchanged)

References (1)
  1. (2024) "Product Information. Crenessity (crinecerfont)." Neurocrine Biosciences, Inc.

Drug and food interactions

Major

pexidartinib food

Applies to: pexidartinib

ADJUST DOSING INTERVAL: The presence of food may increase the absorption and toxicity of pexidartinib. Administration of pexidartinib with a high-fat meal increased peak plasma concentration (Cmax) and systemic exposure (AUC) by 100% and prolonged the time to reach peak plasma concentration (Tmax) by 2.5 hours.

GENERALLY AVOID: Grapefruit or grapefruit juice may increase the plasma concentration and risk of adverse effects of pexidartinib, including potentially fatal hepatotoxicity. The mechanism is inhibition of CYP450 3A4-mediated metabolism of pexidartinib by certain compounds present in grapefruits. Concomitant administration of itraconazole, a strong CYP450 3A4 inhibitor, increased pexidartinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 48% and 70%, respectively.

MANAGEMENT: Pexidartinib should be administered on an empty stomach, at least one hour before or two hours after a meal or snack. Consumption of grapefruit or grapefruit juice should generally be avoided during pexidartinib therapy. If concomitant use is unavoidable, the dose of pexidartinib should be reduced according to the manufacturer's recommendations. If concomitant use of grapefruit or grapefruit juice is discontinued, the dose of pexidartinib may be increased (after 3 plasma half-lives of a strong CYP450 3A4 inhibitor) to the dose that was used prior to consumption of grapefruit or grapefruit juice.

References (1)
  1. (2019) "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc.
Moderate

crinecerfont food

Applies to: crinecerfont

ADJUST DOSING INTERVAL: Coadministration with food increases the oral bioavailability of crinecerfont. Administration of crinecerfont capsules and oral solution with a high-fat meal (800 to 1000 calories, 50% fat), increased crinecerfont peak plasma concentration (Cmax) by 4.9-fold and 8.6-fold, respectively, and systemic exposure (AUC) by 3.3-fold and 8.3-fold, respectively, compared to administration under fasting conditions.

MANAGEMENT: Crinecerfont should be administered twice daily with a meal in the morning and evening without regard to fat or calorie content.

References (1)
  1. (2024) "Product Information. Crenessity (crinecerfont)." Neurocrine Biosciences, Inc.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer